Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inetetamab + pyrotinib
- Development stage
- Phase 2
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **inetetamab**, an anti-HER2 antibody, and **pyrotinib**, an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor. Pyrotinib targets EGFR, HER1, HER2, and HER4, inhibiting tumor cell growth by blocking key signaling pathways. The combination is used for treating HER2-positive advanced breast cancer, particularly in patients who have progressed after trastuzumab treatment.
- Brand names
- AiRuiNi
- Other names
- inetetamab and pyrotinibpyrotinib + inetetamab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on inetetamab + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inetetamab + pyrotinib.